RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignanciesAleksandra Franovic, Estelle Martin, Guodong Li et al.|European Journal of Cancer|2016Cited by 2
RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenesLeona A. Martin, G.G. Li, Christine M. Walsh et al.|European Journal of Cancer|2016Cited by 0